Pancreatic safety of newer incretin-based therapies: are the "-tides" finally turning?

@article{Devaraj2014PancreaticSO,
  title={Pancreatic safety of newer incretin-based therapies: are the "-tides" finally turning?},
  author={Sridevi Devaraj and Anirban Maitra},
  journal={Diabetes},
  year={2014},
  volume={63 7},
  pages={2219-21}
}
Incretin-based therapies have greatly improved therapy of diabetes due to not only their antidiabetic effects but also their beneficial effects on blood pressure, dyslipidemia, reduction in body weight, and potential cardioprotective and neuroprotective effects. The most common of these are glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which act via the G-protein–coupled receptors to stimulate insulin secretion from the pancreatic b-cells in a glucose… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 17 references

Similar Papers

Loading similar papers…